Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non‐small cell lung cancer

Abstract Background Biomarker assessments for nivolumab monotherapy efficacy in previously treated patients with non‐small cell lung cancer (NSCLC) remain unclear. We evaluated whether body mass index (BMI) and Glasgow prognostic score (GPS) are useful for assessing the efficacy of nivolumab alone a...

詳細記述

書誌詳細

出版年:	Thoracic Cancer
主要な著者:	Hisao Imai, Erika Naito, Ou Yamaguchi, Kosuke Hashimoto, Hidetoshi Iemura, Yu Miura, Ayako Shiono, Atsuto Mouri, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu
フォーマット:	論文
言語:	英語
出版事項:	Wiley 2022-05-01
主題:	body mass index carcinoma glasgow prognostic score nivolumab non‐small‐cell lung performance status
オンライン･アクセス:	https://doi.org/10.1111/1759-7714.14417